9th Feb 2024 14:00
Renalytix plc
("Renalytix" or the "Company")
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic
Tools Conference
LONDON and SALT LAKE CITY, February 9, 2024 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will take place February 13-14, 2024 in Snowbird, Utah. Given the format of this event, no formal company presentation is expected. Management will be participating in one-on-one meetings with investors during the event and meetings can be requested through BTIG.
For further information, please contact:
Renalytix plc | www.renalytix.com | |
James McCullough, CEO | Via Walbrook PR | |
|
| |
Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 | |
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea |
| |
|
| |
Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 | |
Gary Clarence / Shalin Bhamra |
| |
|
| |
Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] | |
Paul McManus / Alice Woodings | Mob: 07980 541 893 / 07407 804 654 | |
|
| |
CapComm Partners |
| |
Peter DeNardo | Tel: 415-389-6400 or [email protected] | |
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis? for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
Related Shares:
Renalytix Plc